<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03197480</url>
  </required_header>
  <id_info>
    <org_study_id>R1436/19/2017</org_study_id>
    <nct_id>NCT03197480</nct_id>
  </id_info>
  <brief_title>Diabetic Macular Edema Asian Response (DEAR) Study: Biomarkers for Response to Aflibercept in Asian Patients With Center Involving DME</brief_title>
  <official_title>Identifying Ocular and Systemic Biomarkers for Response to Aflibercept in Asian Patients With Centre Involving Diabetic Macular Edema: A Prospective Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore National Eye Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Santen Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Singapore Eye Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Singapore National Eye Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether ocular imaging and proteomic biomarkers; and systemic biochemical,&#xD;
      metabolomic, and genetic biomarkers predict treatment response to intravitreal aflibercept in&#xD;
      a cohort of patients with DME.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective observational clinical trial with only the use of a standard care of&#xD;
      drug, aflibercept. All study eyes will receive intravitreal aflibercept at the initial&#xD;
      injection and x 4 monthly injections including at month 3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 17, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a prospective observational clinical trial with only the use of a standard care of drug, aflibercept. All study eyes will receive intravitreal aflibercept at the initial injection and x 4 monthly injections including at month 3.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CRT</measure>
    <time_frame>12 Months</time_frame>
    <description>Mean change in Central Retinal Thickness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BCVA</measure>
    <time_frame>12 Months</time_frame>
    <description>Mean change in Best Corrected Visual Acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vascular density by OCTA</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Change in vascular density by OCTA in different layer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a BCVA improvement of 15 letters or more</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Percentage of patients with a BCVA improvement of 15 letters or more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a BCVA improvement of 10 letters or more</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Percentage of patients with a BCVA improvement of 10 letters or more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BCVA at each injection number</measure>
    <time_frame>12 Months</time_frame>
    <description>Mean BCVA at each injection number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in BCVA across all the study injection numbers</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Mean change in BCVA across all the study injection numbers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with BCVA improvement</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Percentage of patients with BCVA improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of BCVA losers</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Percentage of BCVA losers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients improving to 20/40 or better</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Percentage of patients improving to 20/40 or better</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>DME treatment group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients will received 4 intravitreal injections of aflibercept.&#xD;
Based on the OCT outcome they will be classified into 2 groups for assessment of biomarkers:&#xD;
Less than 20% reduction in CRT on OCT or &lt;5 letter improvement of VA (if VA&lt;6/6 and CRT&gt;=340) Rapid (Mac Dry at M4) Delayed: Persistent fluid at M4, but more than 20% reduction in CRT on OCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept Injection [Eylea]</intervention_name>
    <description>All subjects will receive 4 monthly intravitreal injections of aflibercept</description>
    <arm_group_label>DME treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participant&#xD;
&#xD;
          1. Age &gt;=21 years&#xD;
&#xD;
          2. Diagnosis of Diabetes Mellitus (Type 1 or type 2)&#xD;
&#xD;
               1. Current regular use of insulin or oral hypoglycemic agents for treatment of&#xD;
                  diabetes&#xD;
&#xD;
               2. Documented diabetes by ADA and/or WHO criteria.&#xD;
&#xD;
          3. Able and willing to provide informed consent.&#xD;
&#xD;
        Study Eye&#xD;
&#xD;
          1. Best corrected ETDRS visual acuity score &lt;= 78 (ie 20/32 or worse)&#xD;
&#xD;
          2. On Clinical Examination, definite retinal thickening due to diabetic macular edema&#xD;
             involving the center of the macula.&#xD;
&#xD;
          3. Diabetic macular edema present on OCT (central subfield thickness on OCT &gt;=300um with&#xD;
             spectralis (Heidelberg)&#xD;
&#xD;
          4. Media clarity, pupillary dilation and individual cooperation sufficient for study&#xD;
             procedure including fundus photography.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participant&#xD;
&#xD;
          1. End stage renal failure requiring hemodialysis or peritoneal dialysis.&#xD;
&#xD;
          2. Medical condition that, in the opinion of the investigator, would preclude&#xD;
             participation in the study (e.g., unstable medical status including blood pressure,&#xD;
             cardiovascular disease, and glycemic control).&#xD;
&#xD;
          3. Participation in an investigational trial within 30 days of enrolment which involves&#xD;
             treatment with unapproved investigational drug&#xD;
&#xD;
          4. Known allergy to any component of the study drug.&#xD;
&#xD;
          5. Blood pressure &gt; 180/110 (systolic above 180 OR diastolic above 110 on repeated&#xD;
             measurements). If blood pressure is brought below 180/110 by anti-hypertensive&#xD;
             treatment, individual can become eligible.&#xD;
&#xD;
          6. Myocardial infarction, other acute cardiac event requiring hospitalization, stroke,&#xD;
             transient ischemic attack, or treatment for acute congestive heart failure within 4&#xD;
             months prior to randomization.&#xD;
&#xD;
          7. Systemic anti-VEGF or pro-VEGF treatment within three months prior to randomization or&#xD;
             anticipated use during the study.&#xD;
&#xD;
          8. For women of child-bearing potential: pregnant or lactating or intending to become&#xD;
             pregnant within the next 24 months. Women who are potential study participants should&#xD;
             be questioned about the potential for pregnancy.&#xD;
&#xD;
          9. Patient with non study eye VA: counting finger or worse (i.e. only one seeing eye)&#xD;
             will be excluded.&#xD;
&#xD;
        Study Eye&#xD;
&#xD;
          1. Macular edema is considered to be due to a cause other than diabetic macular edema. An&#xD;
             eye should not be considered eligible if: (1) the macular edema is considered to be&#xD;
             related to ocular surgery such as cataract extraction or (2) clinical exam and/or OCT&#xD;
             suggest that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or&#xD;
             epiretinal membrane) are the primary cause of the macular edema.&#xD;
&#xD;
          2. An ocular condition is present such that, in the opinion of the investigator, visual&#xD;
             acuity loss would not improve from resolution of macular edema (e.g., foveal atrophy,&#xD;
             pigment abnormalities, dense subfoveal hard exudates, nonretinal condition).&#xD;
&#xD;
          3. An ocular condition is present (other than diabetes) that, in the opinion of the&#xD;
             investigator, might affect macular edema or alter visual acuity during the course of&#xD;
             the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease,&#xD;
             neovascular glaucoma, etc.)&#xD;
&#xD;
          4. Substantial cataract that, in the opinion of the investigator, is likely to be&#xD;
             decreasing visual acuity by more than three lines (i.e., cataract would be reducing&#xD;
             acuity to worse than 20/40 if eye was otherwise normal).&#xD;
&#xD;
          5. History of an anti-VEGF treatment for DME in the past 3 months or history of any other&#xD;
             treatment for DME at any time in the past 3 months (such as focal/grid macular&#xD;
             photocoagulation, intravitreal or peribulbar corticosteroids).&#xD;
&#xD;
          6. History of pan-retinal photocoagulation within 3 months prior to randomization or&#xD;
             anticipated need for immediate pan-retinal photocoagulation. (eg. Proliferative&#xD;
             diabetic retinopathy. Cases with severe non-proliferative diabetic retinopathy will&#xD;
             still be eligible)&#xD;
&#xD;
          7. History of ocular anti-VEGF treatment for a disease other than DME in the past 3&#xD;
             months&#xD;
&#xD;
          8. History of major ocular surgery (including vitrectomy, cataract extraction, scleral&#xD;
             buckle, any intraocular surgery, etc.) within prior four months or anticipated within&#xD;
             the next six months following randomization.&#xD;
&#xD;
          9. History of YAG capsulotomy performed within two months prior to randomization.&#xD;
&#xD;
         10. Aphakia.&#xD;
&#xD;
         11. Exam evidence of external ocular infection, including conjunctivitis, chalazion, or&#xD;
             significant blepharitis.&#xD;
&#xD;
         12. History of intravitreal steroids within the last 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gavin Tan</last_name>
    <role>Study Director</role>
    <affiliation>Singapore National Eye Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gavin Tan</last_name>
    <phone>6322 7433</phone>
    <email>gavin.tan@singhealth.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Singapore National Eye Centre</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gavin Tan</last_name>
      <email>gavin.tan@singhealth.com.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 5, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>April 18, 2019</last_update_submitted>
  <last_update_submitted_qc>April 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-Vascular Endothelial Growth Factor</keyword>
  <keyword>Aflibercept</keyword>
  <keyword>Intravitreal injection</keyword>
  <keyword>Diabetic Macular Edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT03197480/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

